Bafna Pharmaceuticals Limited Total Assets
Bafna Pharmaceuticals Limited total assets. Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) holds total assets worth Rs1.76 Billion INR (≈ $18.98 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Bafna Pharmaceuticals Limited (BAFNAPH) total market value for the company's overall valuation and market capitalisation.
Total Assets of Bafna Pharmaceuticals Limited (2005–2026)
Total assets of Bafna Pharmaceuticals Limited from 2005 to 2026. This chart illustrates how Bafna Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See Bafna Pharmaceuticals Limited stock quote for real-time trading data and today's change.
Bafna Pharmaceuticals Limited - Asset Composition Analysis
Bafna Pharmaceuticals Limited Total Assets Breakdown (March 2026)
Bafna Pharmaceuticals Limited total assets breakdown as of March 2026. Bafna Pharmaceuticals Limited's total assets of Rs1.76 Billion consist of 51.1% current assets and 48.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.2% |
| Accounts Receivable | Rs440.07 Million | 25.1% |
| Inventory | Rs289.03 Million | 16.5% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2026)
This chart illustrates how Bafna Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Bafna Pharmaceuticals Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bafna Pharmaceuticals Limited's current assets represent 51.1% of total assets in 2026, a decrease from 78.4% in 2005.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2026, down from 6.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 25.1% of total assets.
Bafna Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Bafna Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Bafna Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 1.63 | 2.04 |
| Quick Ratio | 1.06 | 1.09 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs324.62 Million | Rs328.76 Million | Rs253.59 Million |
Bafna Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Bafna Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.94 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 14.7% |
| Total Assets | Rs1.76 Billion |
| Market Capitalization | $116.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bafna Pharmaceuticals Limited's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bafna Pharmaceuticals Limited's assets grew by 14.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bafna Pharmaceuticals Limited (2005–2026)
The table below shows the annual total assets of Bafna Pharmaceuticals Limited from 2005 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs1.76 Billion ≈ $18.98 Million |
+14.67% |
| 2025-03-31 | Rs1.53 Billion ≈ $16.55 Million |
+3.65% |
| 2024-03-31 | Rs1.48 Billion ≈ $15.97 Million |
+13.97% |
| 2023-03-31 | Rs1.30 Billion ≈ $14.01 Million |
+43.75% |
| 2022-03-31 | Rs901.45 Million ≈ $9.75 Million |
+4.25% |
| 2021-03-31 | Rs864.66 Million ≈ $9.35 Million |
+21.25% |
| 2020-03-31 | Rs713.13 Million ≈ $7.71 Million |
-40.31% |
| 2019-03-31 | Rs1.19 Billion ≈ $12.92 Million |
-13.65% |
| 2018-03-31 | Rs1.38 Billion ≈ $14.96 Million |
-22.40% |
| 2017-03-31 | Rs1.78 Billion ≈ $19.28 Million |
-7.38% |
| 2016-03-31 | Rs1.93 Billion ≈ $20.82 Million |
-3.66% |
| 2015-03-31 | Rs2.00 Billion ≈ $21.61 Million |
-15.26% |
| 2014-03-31 | Rs2.36 Billion ≈ $25.50 Million |
-9.50% |
| 2013-03-31 | Rs2.61 Billion ≈ $28.18 Million |
+19.02% |
| 2012-03-31 | Rs2.19 Billion ≈ $23.68 Million |
+61.43% |
| 2011-03-31 | Rs1.36 Billion ≈ $14.67 Million |
+61.21% |
| 2010-03-31 | Rs841.28 Million ≈ $9.10 Million |
+8.09% |
| 2009-03-31 | Rs778.29 Million ≈ $8.42 Million |
+52.23% |
| 2008-03-31 | Rs511.27 Million ≈ $5.53 Million |
-5.34% |
| 2007-03-31 | Rs540.09 Million ≈ $5.84 Million |
+151.65% |
| 2006-03-31 | Rs214.62 Million ≈ $2.32 Million |
+27.36% |
| 2005-03-31 | Rs168.51 Million ≈ $1.82 Million |
-- |
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more